ADAR1 Capital Management LLC raised its holdings in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 381.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 149,385 shares of the company's stock after purchasing an additional 118,333 shares during the quarter. ADAR1 Capital Management LLC owned 0.47% of Delcath Systems worth $1,799,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in the stock. Geode Capital Management LLC lifted its holdings in Delcath Systems by 14.7% during the 4th quarter. Geode Capital Management LLC now owns 288,951 shares of the company's stock valued at $3,481,000 after buying an additional 37,056 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of Delcath Systems by 28.8% during the fourth quarter. Principal Financial Group Inc. now owns 115,183 shares of the company's stock worth $1,387,000 after acquiring an additional 25,736 shares during the period. Diametric Capital LP raised its stake in shares of Delcath Systems by 39.6% during the fourth quarter. Diametric Capital LP now owns 94,737 shares of the company's stock valued at $1,141,000 after acquiring an additional 26,881 shares in the last quarter. State Street Corp boosted its holdings in shares of Delcath Systems by 12.4% in the third quarter. State Street Corp now owns 85,457 shares of the company's stock valued at $772,000 after purchasing an additional 9,400 shares during the period. Finally, ExodusPoint Capital Management LP boosted its holdings in shares of Delcath Systems by 32.2% in the fourth quarter. ExodusPoint Capital Management LP now owns 51,697 shares of the company's stock valued at $622,000 after purchasing an additional 12,604 shares during the period. 61.12% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of brokerages have weighed in on DCTH. HC Wainwright lifted their target price on Delcath Systems from $22.00 to $24.00 and gave the company a "buy" rating in a research report on Friday, March 7th. Craig Hallum increased their target price on shares of Delcath Systems from $18.00 to $21.00 and gave the stock a "buy" rating in a report on Friday, January 17th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, Delcath Systems presently has an average rating of "Moderate Buy" and a consensus price target of $22.75.
View Our Latest Stock Report on Delcath Systems
Delcath Systems Stock Performance
DCTH stock traded up $0.13 during trading on Friday, reaching $10.66. 371,703 shares of the company traded hands, compared to its average volume of 352,162. The business has a 50 day simple moving average of $13.59 and a 200 day simple moving average of $12.19. Delcath Systems, Inc. has a 12 month low of $4.26 and a 12 month high of $16.97. The company has a market capitalization of $356.40 million, a price-to-earnings ratio of -7.90 and a beta of 0.85.
Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its quarterly earnings results on Thursday, March 6th. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. The firm had revenue of $15.10 million during the quarter, compared to the consensus estimate of $14.96 million. During the same quarter in the prior year, the business posted ($0.48) earnings per share. As a group, research analysts forecast that Delcath Systems, Inc. will post -0.79 EPS for the current year.
About Delcath Systems
(
Free Report)
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Featured Stories
Before you consider Delcath Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Delcath Systems wasn't on the list.
While Delcath Systems currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
